Supplementary Materials

The PDF file includes:

  • Fig. S1. Tissue persistence of ARC-0704 T. cruzi strain pre- and post-full course BNZ treatment in chronically infected mice.
  • Fig. S2. BNZ given weekly over 37 weeks cures mice with chronic T. cruzi infections.
  • Fig. S3. Parasites recovered from mice treated for 55 weeks with 100 mg/kg of BNZ (100w/STOP) had unchanged susceptibility to BNZ in vitro.
  • Fig. S4. 3D reconstruction of whole organs from uninfected C57BL/6 mice.
  • Fig. S5. T. cruzi clearance as assessed by whole-organ LSFM.
  • Fig. S6. Drug dose–dependent differential clearance of an established T. cruzi infection as assessed by confocal microscopy.
  • Fig. S7. CUBIC tissue clarification protocols preserve fluorescence in dye-stained parasites.
  • Table S1. Automated quantification of total tdTomato-positive amastigote nests or total DiR-positive dormant parasites in tissues of untreated and treated mice with 500 mg/kg of BNZ.
  • Table S2. Automated quantification of total DiR-positive dormant parasites from the experiment performed in Fig. 5 and fig. S5.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Movie S1 (.mov format). Nearly unrestricted expansion of T. cruzi amastigote nests in heart and skeletal muscle in IFN-γ–deficient mice.
  • Movie S2 (.mov format). Uncontrolled T. cruzi development in IFN-γ–deficient mice.
  • Movie S3 (.mov format). Controlled T. cruzi amastigote nests in infected C57BL/6 wild-type mice.
  • Movie S4 (.mov format). Partial clearance of T. cruzi parasites following brief BNZ treatment.
  • Movie S5 (.mov format). Multicolor light sheet microscopy reveals active and dormant parasite clearance following weekly BNZ treatment.
  • Raw data file. Raw data file.xlsx.